These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33214781)

  • 21. [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].
    Botsios C; Ostuni P; Todesco S
    Reumatismo; 2005; 57(1):44-51. PubMed ID: 15776146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab.
    Zeng-Wang YM; Cares K; Thomas R; El-Baba M
    Gastroenterol Nurs; 2021 Nov-Dec 01; 44(6):449-454. PubMed ID: 34690297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.
    Saxena P; Chen G; Jideh B; Collins G; Leong RW
    Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
    Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
    Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
    Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
    World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit.
    Sandberg KC; Lucien JN; Stoll D; Yanney E; Mezoff A
    Pediatr Qual Saf; 2019; 4(1):e131. PubMed ID: 30937413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
    Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
    J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
    Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
    Stephens MC; Shepanski MA; Mamula P; Markowitz JE; Brown KA; Baldassano RN
    Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
    van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?
    Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
    Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.